ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL58323
CHEMBL58323
Compound Name ERLOSAMIDE
ChEMBL Synonyms Erlosamide | SPM 927 | VIMPAT | ADD 243037 | LACOSAMIDE
Max Phase 4 (Approved)
Trade Names VIMPAT | LACOSAMIDE
Molecular Formula C13H18N2O3

Additional synonyms for CHEMBL58323 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES COC[C@@H](NC(=O)C)C(=O)NCc1ccccc1
Standard InChI InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4- ...
Download InChI
Standard InChI Key VPPJLAIAVCUEMN-GFCCVEGCSA-N

Sources

  • British National Formulary
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL58323

Molecule Features

CHEMBL58323 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:Y Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Sodium channel alpha subunit blocker Sodium channel alpha subunit FDA PubMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
AlcoholismD000437EFO:0003829alcohol dependence1ClinicalTrials
Amyotrophic Lateral SclerosisD000690EFO:0000253amyotrophic lateral sclerosis1ClinicalTrials
DementiaD003704HP:0000726dementia3ClinicalTrials
Diabetic NeuropathiesD003929EFO:1000783diabetic neuropathy3ClinicalTrials
EpilepsyD004827EFO:0000474epilepsy4ATC
ClinicalTrials
Migraine DisordersD008881EFO:0003821migraine disorder2ClinicalTrials
SeizuresD012640EFO:0000474epilepsy4DailyMed
DailyMed
Epilepsies, PartialD004828EFO:0004263partial epilepsy3ClinicalTrials
NeuralgiaD009437EFO:0005762neuropathic pain2ClinicalTrials
SchizophreniaD012559EFO:0000692schizophrenia3ClinicalTrials
Depressive DisorderD003866EFO:0003761unipolar depression3ClinicalTrials
FibromyalgiaD005356EFO:0005687fibromyalgia2ClinicalTrials
OsteoarthritisD010003EFO:0002506osteoarthritis2ClinicalTrials
SeizuresD012640HP:0001250Seizures4ClinicalTrials
AnxietyD001007EFO:0005230anxiety3ClinicalTrials
Peripheral Nervous System DiseasesD010523EFO:0004149neuropathy3ClinicalTrials

Clinical Data

ClinicalTrials.gov ERLOSAMIDE
The Cochrane Collaboration ERLOSAMIDE

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL58323. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL3891 Calpain 1 Homo sapiens 1.000
CHEMBL2581 Cathepsin D Homo sapiens 0.999
CHEMBL4662 Proteasome Macropain subunit MB1 Homo sapiens 0.995
CHEMBL286 Renin Homo sapiens 0.989
CHEMBL333 Matrix metalloproteinase-2 Homo sapiens 0.976
CHEMBL321 Matrix metalloproteinase 9 Homo sapiens 0.934
CHEMBL283 Matrix metalloproteinase 3 Homo sapiens 0.882
CHEMBL4801 Caspase-1 Homo sapiens 0.756
CHEMBL2026 Beta-lactamase AmpC Escherichia coli K-12 0.748
CHEMBL4779 Papain Carica papaya 0.717
CHEMBL332 Matrix metalloproteinase-1 Homo sapiens 0.711
CHEMBL204 Thrombin Homo sapiens 0.671
CHEMBL4588 Matrix metalloproteinase 8 Homo sapiens 0.305
CHEMBL4072 Cathepsin B Homo sapiens 0.304
CHEMBL3563 Cruzipain Trypanosoma cruzi 0.285
CHEMBL2334 Caspase-3 Homo sapiens 0.238



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL3891 Calpain 1 Homo sapiens 1.000
CHEMBL2581 Cathepsin D Homo sapiens 0.996
CHEMBL286 Renin Homo sapiens 0.986
CHEMBL4662 Proteasome Macropain subunit MB1 Homo sapiens 0.971
CHEMBL333 Matrix metalloproteinase-2 Homo sapiens 0.899
CHEMBL332 Matrix metalloproteinase-1 Homo sapiens 0.885
CHEMBL2323 Cathepsin B Bos taurus 0.800
CHEMBL283 Matrix metalloproteinase 3 Homo sapiens 0.783
CHEMBL204 Thrombin Homo sapiens 0.707
CHEMBL2590 Aminopeptidase N Sus scrofa 0.701
CHEMBL321 Matrix metalloproteinase 9 Homo sapiens 0.698
CHEMBL2026 Beta-lactamase AmpC Escherichia coli K-12 0.693
CHEMBL4779 Papain Carica papaya 0.507
CHEMBL4801 Caspase-1 Homo sapiens 0.437
CHEMBL4588 Matrix metalloproteinase 8 Homo sapiens 0.341
CHEMBL1963 Thyroid stimulating hormone receptor Homo sapiens 0.303
CHEMBL209 Trypsin I Homo sapiens 0.241

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
250.3 250.1317 0.45 6 67.43 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
3 2 0 5 2 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- - .73 .73 1 18 0.77

Structural Alerts

There are 2 structural alerts for CHEMBL58323. To view alerts please click here.

Compound Cross References

ATC N - NERVOUS SYSTEM
N03 - ANTIEPILEPTICS
N03A - ANTIEPILEPTICS
N03AX - Other antiepileptics
N03AX18 - lacosamide

ChemSpider ChemSpider:VPPJLAIAVCUEMN-GFCCVEGCSA-N
DailyMed lacosamide
PubChem SID: 170466190
Wikipedia Lacosamide

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL58323



ACToR 175481-36-4
BindingDB 50300204
ChEBI 135939
ChemicalBook CB41011740
DrugBank DB06218
DrugCentral 4310
eMolecules 10613314
EPA CompTox Dashboard DTXSID1057666
FDA SRS 563KS2PQY5
Guide to Pharmacology 7472
IBM Patent System DB42E38423162965353B9732DAFD24A1
LINCS LSM-45385
Mcule MCULE-8848296606
Nikkaji J1.029.117H
PharmGKB PA166160048
PubChem 219078
PubChem: Drugs of the Future 12015335
PubChem: Thomson Pharma 15196715 14847708
SureChEMBL SCHEMBL35330
ZINC ZINC000000007673

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/VPPJLAIAVCUEMN-GFCCVEGCSA-N spacer
spacer